A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors ABBV-711, Budigalimab - Advanced Squamous Tumors Phase 1 Recruiting AbbVie 220 2025-11-20 2026-08-19 Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations Telisotuzumab Adizutecan, Budigalimab, Pembrolizumab - Non Small Cell Lung Carcinoma, c-MET Phase 1 / Phase 2 Recruiting AbbVie 252 2025-03-06 2026-10-20 Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) Livmoniplimab, Budigalimab, Docetaxel - Urothelial Carcinoma Phase 2 Active not recruiting AbbVie 150 2025-01-20 2025-08-11 A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Telisotuzumab Adizutecan, Budigalimab, Fluorouracil - Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Phase 2 Active not recruiting AbbVie 185 2024-12-13 2026-07-21 A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Livmoniplimab, Budigalimab - Hepatocellular Carcinoma (HCC) Phase 1 Terminated AbbVie 3 2024-09-11 2026-10-21 Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Livmoniplimab, Budigalimab, Pembrolizumab - Non-Small Cell Lung Cancer Phase 2 / Phase 3 Active not recruiting AbbVie 167 2024-04-10 2026-10-19 Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients TTX-030, nab-paclitaxel and gemcitabine, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, Nab-Paclitaxel and gemcitabine - Pancreatic Cancer Phase 2 Completed Trishula Therapeutics, Inc. 194 2024-03-25 2026-05-13 A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors ABBV-303, Budigalimab - Solid Tumors Phase 1 Terminated AbbVie 27 2024-02-06 2025-10-27 A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) Livmoniplimab, Budigalimab, Durvalumab - Hepatocellular Carcinoma Phase 2 / Phase 3 Active not recruiting AbbVie 89 2024-01-11 2026-09-22 A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382 Budigalimab, Placebo for Budigalimab, ABBV-382 - Human Immuno-deficiency Virus (HIV) Disease Phase 2 Terminated AbbVie 163 2023-10-12 2025-10-29 Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) Budigalimab, Livmoniplimab, Lenvatinib - Hepatocellular Carcinoma Phase 2 Active not recruiting AbbVie 130 2023-09-21 2025-08-14 Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors ABBV-706, Cisplatin, Budigalimab - Advanced Solid Tumors Phase 1 Active not recruiting AbbVie 288 2022-12-05 2026-05-07 Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan Azirkitug, Budigalimab, Bevacizumab - Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma Phase 1 Recruiting AbbVie 694 2021-11-01 2026-06-23 Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis ABBV-927, Budiglimab, modified FOLFIRINOX - Pancreatic Cancer Phase 1 Terminated AbbVie 40 2021-05-28 2025-01-07 Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV) Budigalimab, Placebo - Human Immunodeficiency Virus (HIV) Phase 1 Completed AbbVie 33 2021-03-15 2022-10-17 TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6 - Solid Tumor, Adult Phase 1 Completed Trishula Therapeutics, Inc. 185 2020-03-30 2025-07-29 A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1 ABBV-181, Placebo - Human Immunodeficiency Virus (HIV), HIV Infection Phase 1 Completed AbbVie 41 2020-01-30 2023-03-09 A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma ABBV-181, ABBV-368, ABBV-927 - Head and Neck Cancer Phase 1 Terminated AbbVie 3 2020-01-22 2020-12-31 A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma ABBV-368, Tilsotolimod, Nab-paclitaxel - Advanced Solid Tumors Cancer Phase 1 Completed AbbVie 30 2020-01-22 2023-02-27 A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors ABBV-927, ABBV-368, ABBV-181 - Cancer, Advanced Solid Tumors Phase 1 Active not recruiting AbbVie 150 2019-05-21 2026-09-02